Many Investors Still Treating Gilead: 4 Launches This Year Could Prove Them Wrong
Gilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
This overview explains what an index reading reveals about market conditions and potential moves, with tips to apply the signals in practice.
20,664 articlesGilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
A sharp upgrade, new AI partnerships, and a strategic move to Miami illuminate Palantir's potential. Learn how these ...
As Life360 maps its path into 2025, investors face a pivotal question: will the life360 (lif) 2025 earnings story hin...
Intuitive Machines stock popped today as analysts weigh backlog, milestones, and funding signals. This article breaks...
Rivian has captured imaginations—and capital. But the next 12 months will test its ability to scale, control costs, a...
When Nvidia posts a blowout quarter, investors often wonder if the stock remains a smart buy. This article weighs his...
This morning’s update centers on a massive Zcash exploit found by a security researcher. The flaw may have lingered f...
Investors often ask where will fluor stock head next. This guide lays out base, bull, and bear scenarios, plus concre...
A coalition-backed stablecoin launches as a potential disruptor to USDC. This shift could reshape how institutions ea...
SoundHound AI is pursuing an enterprise voice AI niche built on data ownership and brand protection. This article bre...
February delivered a sharp 21.4% drop for BigBear.AI, widening concerns about AI stocks. This guide breaks down the d...
In San Francisco, activists and industry critics gathered outside AI hubs to demand a pause on fast-paced development...